NCT07543601Recruiting
Enhanced COPD Management in Suspected Lung Cancer Patients
Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates. This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- First submitted
- 13 Mar 2026
- Start date
- 6 Mar 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Ditte Krag-Hansen
- Diseases
- COPD, Lung cancer
- NCT number
- NCT07543601
What you commit to
- Study type: Interventional
- Planned participants: 280
- From 6 Mar 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry
- Pregnant or breastfeeding women
Who the study is looking for
- Undergoing diagnostic evaluation for suspected lung cancer
- Spirometry showing obstructive airflow limitation (FEV₁/FVC \< 75 % or FEV₁ \< 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lung Cancer Investigation Unit, Lillebaelt Hospital Vejle Coordinator of this site? Confirm its status | Vejle | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.